NAD⁺ & Healthy Aging: Expert Review on Supplements, Research & Potential Benefits

The search for interventions that can slow the effects of aging and mitigate neurodegenerative diseases like Alzheimer’s and Parkinson’s has focused increasingly on a molecule called nicotinamide adenine dinucleotide, or NAD⁺. A new expert review, published in Nature Aging, consolidates years of research and clinical studies exploring ways to boost NAD⁺ levels, offering a roadmap for future research and potential clinical applications.

The Role of NAD⁺ in Cellular Health

NAD⁺ is often described as a cell’s “fuel regulator,” playing a vital role in energy production, DNA repair, and overall cellular function. However, levels of this crucial molecule naturally decline with age, a decrease linked to a range of age-related health problems, including memory loss and reduced muscle strength. Researchers are now investigating whether increasing NAD⁺ levels can counteract these declines and potentially delay or prevent the onset of debilitating diseases. This isn’t a new area of inquiry; the link between declining NAD⁺ and age-related illness has been explored for some time, but the recent review represents a significant effort to synthesize the current understanding and chart a course forward.

Dr. Jianying Zhang, one of the lead authors of the review, emphasizes the require for careful investigation. “Fine-tuning NAD⁺ metabolism holds promise for delaying age-related health decline as well as disease such as premature ageing diseases,” she says. “But to truly unlock its potential, we need to better understand the right doses, long-term safety, and interindividual variability in response to NAD⁺ augmentation strategies.”

Exploring NAD⁺ Boosting Compounds: NR and NMN

Many approaches to raising NAD⁺ levels focus on precursors – compounds the body uses to create NAD⁺. Two of the most studied are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Early clinical trials have shown promising results, with some studies reporting improvements in memory, physical function, and metabolic health. For example, research led by Associate Professor Evandro Fei Fang from the University of Oslo and Akershus University Hospital, Norway, has shown that boosting NAD⁺ can reverse neurological deficits in Alzheimer’s disease models by regulating RNA splicing – a process crucial for brain health. More on this research is available from EurekAlert!

However, the researchers caution that these early findings require confirmation through larger, longer-term studies. The review highlights the importance of rigorous clinical testing to determine the effectiveness of these approaches across different diseases and populations. It’s crucial to remember that results observed in animal models don’t always translate directly to humans.

A Growing Market and the Need for Scientific Rigor

Interest in NAD⁺ therapies is surging, both within the scientific community and among the general public. Clinical trials are underway globally, including in Norway, to assess the potential of NR and NMN. Simultaneously, a rapidly expanding market for NAD⁺ supplements has emerged, raising questions about product quality, efficacy, and safety. This has created a landscape where consumers are faced with a multitude of options, often lacking clear scientific backing.

Dr. Evandro Fei Fang-Stavem, senior author of the review and head of the Fang Lab at UiO and Ahus, underscores the need for clarity. “NAD⁺ is fundamental to life, yet there is still confusion and noise in the field about which supplements work best and how they should be used. Our article consolidates the evidence and provides a scientific roadmap to guide both ongoing research and future clinical use.” Learn more about Dr. Fang-Stavem’s research at the University of Oslo.

Understanding the Mechanisms: Beyond Boosting Levels

The review doesn’t simply focus on raising NAD⁺ levels; it delves into the complex mechanisms by which this molecule exerts its effects. Researchers are exploring how NAD⁺ influences various cellular processes, including DNA repair, mitochondrial function, and inflammation. Understanding these mechanisms is crucial for developing targeted therapies that can maximize the benefits of NAD⁺ augmentation.

Professor Torbjørn Omland, Deputy Head of the Institute of Clinical Medicine and a co-author of the paper, notes the importance of bridging the knowledge gap between basic research and clinical practice. “There is a knowledge gap on NAD⁺ and its clinical effects to basic researchers and clinicians, and this review paper provides the latest expert opinion to those who are interested in and are working in the field NAD⁺ research. This review will too provide relevant information to many NAD⁺-based clinical trials across a wide spectrum of clinical conditions, including neurological and cardiovascular disease.”

The Importance of Collaboration and Future Directions

The authors emphasize that progress in this field requires strong collaboration and rigorous clinical testing. The review highlights the contributions of researchers from multiple institutions across Norway, Denmark, Japan, the United States, and other countries. This international collaboration is essential for accelerating the pace of discovery and translating research findings into effective treatments.

The review also points to several key areas for future research, including the development of biomarkers to monitor NAD⁺ levels and assess the effectiveness of interventions, and the investigation of personalized approaches to NAD⁺ augmentation based on individual genetic and metabolic profiles. ScienceDaily provides further details on the study’s findings.

What’s Next for NAD⁺ Research?

The field of NAD⁺ research is rapidly evolving. Ongoing clinical trials will provide crucial data on the safety and efficacy of NR and NMN, and researchers are continuing to explore new ways to boost NAD⁺ levels and harness its therapeutic potential. Expect to see continued debate and refinement of understanding as more evidence emerges. The focus will likely shift towards identifying specific patient populations who are most likely to benefit from NAD⁺-based therapies and developing personalized treatment strategies. The scientific community is also prioritizing the development of standardized methods for measuring NAD⁺ levels and assessing the impact of interventions, ensuring greater consistency and comparability across studies.